Stryker Corporation (SYK) Investigation

The investigation is focused on the propriety of Stryker’s disclosures about its Inari Medical operations and growth prospects. Stryker acquired Inari in February 2025 to supplement Stryker’s Peripheral Vascular reporting unit.

On July 30, 2026, Stryker reported its Q2 2026 results and said, without providing details, that it faced supply disruptions in the Peripheral Vascular unit and that the disruption resulted in “a meaningful backorder situation with lost sales in the quarter.” Nonetheless, management assured investors that “[w]e have addressed the issue and backorder should reach a manageable level by the end of Q3.”

During the related earnings call that day, an analyst asked for some color on the disruption and what exactly happened. CEO Kevin Lobo said, “I’m not going to get into the details of what it was, but let’s just say it did cause a significant backorder specific to one plant in the Inari business,” and “[t]he backorder is pretty elevated right now.”

In response, the market sent the price of Stryker shares down $22.34 (-6.4%) the next day.

Then, during the September 8, 2026 Wells Fargo Healthcare Conference, CFO Preston Wells further described the manufacturing issue as “not allowing us to reach a full supply of inventory at all of our customers[]” and “quite frankly, not allowing us to go out and really win new business.”

Most concerning was his revelation that, in contrast to previous assurances, the problem “is continuing into the third quarter and will certainly continue – we expect it to continue a little bit into the fourth quarter as well.”

The market negatively reacted again, sending the price of Stryker shares sharply lower that day.

FREQUENTLY ASKED QUESTIONS ABOUT THE CASE

What is the SYK investigation about?

We are focused on when Stryker knew its Peripheral Vascular manufacturing problem hadn’t been resolved and would persist beyond Q3.

WHAT SHOULD I DO?

I worked at SYK. What should I do?

If you were an employee of SYK, you may have valuable information that could be relevant to the investigation. Hagens Berman is one of the nation’s top whistleblower law firms, and has successfully represented many individuals who come forward with information regarding corporate malfeasance. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, contact Reed Kathrein at 844-916-0895 or [email protected].

There are multiple law firms participating, do I need to contact all of them?

No, you do not need to contact all participating law firms. Generally, class-action investigations and lawsuits are consolidated into a single case to streamline the legal process, and attorneys from only a few law firms are selected to serve in a leadership role on the consolidated case. Hagens Berman has a proven track record of being appointed to leadership roles in complex, multidistrict litigation regarding investor fraud and other consumer rights issues, and your claim will be handled by attorneys who have helped secure approximately $325 billion in class-action settlements on behalf of individuals who have suffered due to corporate malfeasance and the wrongdoing of other powerful institutions.

AM I ELIGIBLE?

What is the threshold amount to be eligible? What are “substantial” losses?

The threshold amount and the definition of "substantial" losses may vary depending on a number of factors specific to the case, including the size of the company, market cap, shares outstanding and who holds them and the damages alleged by the fraud. In general, to be eligible to participate in a class-action lawsuit, you must be able to demonstrate that you suffered financial losses as a result of the alleged wrongdoing and that your losses meet the criteria set by the court or law firm. Fill out the form and submit your losses.

CAN I PARTICIPATE?

Am I affected? What do I need to do to participate?

If you were an investor in SYK, you may be affected and eligible to participate in the case. To determine your eligibility and potential involvement, fill out the form and submit your losses.

Can any SYK investor participate?

In most class-action investigations and cases, any investor who meets the eligibility criteria, including purchasing the shares during the relevant period, can participate, regardless of the size of their investment. Fill out the form to find out your rights.

I bought on a non-U.S. Exchange. Can I participate?

No. This investigation only covers shares bought on a U.S. exchange, i.e. NASDAQ or NYSE. Fill out the form to find out your rights.

Am I included if I still hold my shares, or do I need to sell to participate?

Participation is based on purchasing shares during the relevant period, rather than your current holdings. Accordingly, you do not need to sell to participate. Fill out the form to find out your rights.